Rocket Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Rocket Pharmaceuticals, Inc. (RCKT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 730.50 thousand shares for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-23.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2016-03-23
- Rocket Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-12-31 was 91.50K shares.
- Rocket Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-09-30 was -482.36M shares.
- Rocket Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-06-30 was 483.00M shares.
- Rocket Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-03-31 was 0.00 shares.
- Rocket Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2015 was 730.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2015-12-31 | 91.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | -482.27M shares derived: sum of 2 quarters · filed 2016-03-23 | 730.50K shares derived: sum of 3 quarters · filed 2016-03-23 | 730.50K shares 10-K · filed 2016-03-23 |
| 2015-09-30 | -482.36M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 639.00K shares derived: sum of 2 quarters · filed 2015-11-12 | 639.00K shares 10-Q · filed 2015-11-12 | |
| 2015-06-30 | 483.00M shares 10-Q · filed 2015-08-07 | 483.00M shares 10-Q · filed 2015-08-07 | ||
| 2015-03-31 | 0.00 shares derived: 10-K 12 month − 3 quarters · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |